Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avichai Shimoni

Showing results (61-70 of 165) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|August 1, 2025
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II studyIvetta Danylesko, Avichai Shimoni, Abraham Avigdor, et al.
Blood Advances|June 22, 2019
External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantationRoni Shouval, Joshua A Fein, Aniela Shouval, et al.
Journal of Leukocyte Biology|December 10, 2013
Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNPOlga Ostrovsky, Avichai Shimoni, Polina Baryakh, et al.
The Israel Medical Association Journal : IMAJ|May 20, 2014
Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysisArie Apel, Meirav Kedmi, Etai Levi, et al.
Cancer|January 19, 2012
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphomaAvichai Shimoni, Irit Avivi, Jacob M Rowe, et al.
Cancer|June 22, 2010
Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-upAvichai Shimoni, Izhar Hardan, Francis Ayuk, et al.
Current Research in Translational Medicine|September 21, 2024
Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expressionIvetta Danylesko, Noga Shem-Tov, Ronit Yerushalmi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2015
Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia PatientsMaya Koren-Michowitz, Avichai Shimoni, Filomena Daraio, et al.
Experimental Hematology|March 24, 2007
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphomaAvichai Shimoni, S Tzila Zwas, Yakov Oksman, et al.
Bone Marrow Transplantation|February 28, 2019
Early and late hematologic toxicity following CD19 CAR-T cellsShalev Fried, Abraham Avigdor, Bella Bielorai, et al.
Pageof 17

Showing results (61-70 of 165) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|August 1, 2025
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II studyIvetta Danylesko, Avichai Shimoni, Abraham Avigdor, et al.
Blood Advances|June 22, 2019
External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantationRoni Shouval, Joshua A Fein, Aniela Shouval, et al.
Journal of Leukocyte Biology|December 10, 2013
Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNPOlga Ostrovsky, Avichai Shimoni, Polina Baryakh, et al.
The Israel Medical Association Journal : IMAJ|May 20, 2014
Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysisArie Apel, Meirav Kedmi, Etai Levi, et al.
Cancer|January 19, 2012
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphomaAvichai Shimoni, Irit Avivi, Jacob M Rowe, et al.
Cancer|June 22, 2010
Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-upAvichai Shimoni, Izhar Hardan, Francis Ayuk, et al.
Current Research in Translational Medicine|September 21, 2024
Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expressionIvetta Danylesko, Noga Shem-Tov, Ronit Yerushalmi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2015
Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia PatientsMaya Koren-Michowitz, Avichai Shimoni, Filomena Daraio, et al.
Experimental Hematology|March 24, 2007
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphomaAvichai Shimoni, S Tzila Zwas, Yakov Oksman, et al.
Bone Marrow Transplantation|February 28, 2019
Early and late hematologic toxicity following CD19 CAR-T cellsShalev Fried, Abraham Avigdor, Bella Bielorai, et al.
Pageof 17